AstraZeneca's Arimidex has shown in trials it does a much better job of preventing the recurrence of breast cancer than the popular tamoxifen, according to a study in the journal Lancet. The study, funded by AstraZeneca, said Arimidex could defend against up to 80% of the most common types of tumors that occur after menopause, compared with a 50% rate attributed to tamoxifen.

Related Summaries